相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity
Yannick Cyr et al.
OBESITY (2020)
LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
May Faraj
JOURNAL OF BIOMEDICAL RESEARCH (2020)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
The Association of Polyunsaturated Fatty Acid δ-5-Desaturase Activity with Risk Factors for Type 2 Diabetes Is Dependent on Plasma ApoB-Lipoproteins in Overweight and Obese Adults
Valerie Lamantia et al.
JOURNAL OF NUTRITION (2019)
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson et al.
NATURE REVIEWS IMMUNOLOGY (2019)
High plasma apolipoprotein B identifies obese subjects who best ameliorate white adipose tissue dysfunction and glucose-induced hyperinsulinemia after a hypocaloric diet
Simon Bissonnette et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2018)
Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization
Jan F. C. Glatz et al.
JOURNAL OF LIPID RESEARCH (2018)
Questioning the safety and benefits of evolocumab
Luca Mascitelli et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
ApoB-lipoproteins and dysfunctional white adipose tissue: Relation to risk factors for type 2 diabetes in humans
Valerie Lamantia et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Metabolic injury-induced NLRP3 inflammasome activation dampens phospholipid degradation
Elena Rampanelli et al.
SCIENTIFIC REPORTS (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Amand F. Schmidt et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study
Amalia Gastaldelli et al.
DIABETES (2017)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis
Luca A. Lotta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects
Yannick Cyr et al.
JOURNAL OF LIPID RESEARCH (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver
Annie Demers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans
Hanny Wassef et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Daniel I. Swerdlow et al.
LANCET (2015)
Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma
Sascha Sauer
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans
S. Bissonnette et al.
NUTRITION & DIABETES (2015)
Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study
Giovanni Corrao et al.
DIABETES CARE (2014)
Caspases and inflammasomes in metabolic inflammation
Alexander M. Skeldon et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in PatientsWith Type 2 Diabetes
Joanne Sloan-Lancaster et al.
DIABETES CARE (2013)
Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue
Simon Bissonnette et al.
JOURNAL OF LIPID RESEARCH (2013)
Important considerations for protein analyses using antibody based techniques: down-sizing Western blotting up-sizes outcomes
Robyn M. Murphy et al.
JOURNAL OF PHYSIOLOGY-LONDON (2013)
CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation
Frederick J. Sheedy et al.
NATURE IMMUNOLOGY (2013)
White Adipose Tissue Apolipoprotein C-I Secretion in Relation to Delayed Plasma Clearance of Dietary Fat in Humans
Hanny Wassef et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Claudia Cavelti-Weder et al.
DIABETES CARE (2012)
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Paul M. Ridker et al.
LANCET (2012)
The Inflammasome and Caspase-1 Activation: A New Mechanism Underlying Increased Inflammatory Activity in Human Visceral Adipose Tissue
Tim B. Koenen et al.
ENDOCRINOLOGY (2011)
Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Haitao Wen et al.
NATURE IMMUNOLOGY (2011)
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Bolormaa Vandanmagsar et al.
NATURE MEDICINE (2011)
The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity
Rinke Stienstra et al.
CELL METABOLISM (2010)
Adipocyte Turnover: Relevance to Human Adipose Tissue Morphology
Erik Arner et al.
DIABETES (2010)
Disposition Index, Glucose Effectiveness, and Conversion to Type 2 Diabetes The Insulin Resistance Atherosclerosis Study (IRAS)
Carlos Lorenzo et al.
DIABETES CARE (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
Robert J. Schmidt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale
Martina I. Lefterova et al.
GENES & DEVELOPMENT (2008)
Human SGBS Cells - a Unique Tool for Studies of Human Fat Cell Biology
Pamela Fischer-Posovszky et al.
OBESITY FACTS (2008)
Adipogenesis and lipotoxicity:: role of peroxisome proliferator-activated receptor γ (PPARγ) and PPARγcoactivator-1 (PGC1)
Gema Medina-Gomez et al.
PUBLIC HEALTH NUTRITION (2007)
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Claus M. Larsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes
M Faraj et al.
JOURNAL OF LIPID RESEARCH (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
A role for C/EBPβ in regulating peroxisome proliferator-activated receptor γ activity during adipogenesis in 3T3-L1 preadipocytes
JK Hamm et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
